| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Acadia Healthcare Co (NASDAQ:ACHC) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 3 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 2 | 1 | 0 | 0 |
| 3M Ago | 3 | 0 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $26.1, a high estimate of $31.00, and a low estimate of $20.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 24.57%.
The standing of Acadia Healthcare Co among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $25.00 | $25.00 |
| John Ransom | Raymond James | Raises | Outperform | $30.00 | $26.00 |
| Joanna Gajuk | B of A Securities | Lowers | Neutral | $25.00 | $27.00 |
| John Ransom | Raymond James | Lowers | Outperform | $26.00 | $40.00 |
| Ann Hynes | Mizuho | Lowers | Neutral | $22.00 | $32.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $28.00 | $43.00 |
| Gary Taylor | TD Cowen | Lowers | Buy | $25.00 | $44.00 |
| Andrew Mok | UBS | Lowers | Buy | $31.00 | $45.00 |
| Jason Cassorla | Guggenheim | Lowers | Buy | $29.00 | $36.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $20.00 | $28.00 |
To gain a panoramic view of Acadia Healthcare Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Acadia Healthcare Co analyst ratings.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Acadia Healthcare Co displayed positive results in 3M. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 9.19%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's net margin excels beyond industry benchmarks, reaching 3.47%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Acadia Healthcare Co's ROE excels beyond industry benchmarks, reaching 0.98%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Acadia Healthcare Co's ROA excels beyond industry benchmarks, reaching 0.48%. This signifies efficient management of assets and strong financial health.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below the industry average. With a ratio of 0.78, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ACHC
